BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30623789)

  • 1. Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer.
    Zhou P; Qin J; Zhou C; Wan G; Liu Y; Zhang M; Yang X; Zhang N; Wang Y
    Biomaterials; 2019 Mar; 195():86-99. PubMed ID: 30623789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
    Rodell CB; Arlauckas SP; Cuccarese MF; Garris CS; Li R; Ahmed MS; Kohler RH; Pittet MJ; Weissleder R
    Nat Biomed Eng; 2018 Aug; 2(8):578-588. PubMed ID: 31015631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors.
    Bahmani B; Gong H; Luk BT; Haushalter KJ; DeTeresa E; Previti M; Zhou J; Gao W; Bui JD; Zhang L; Fang RH; Zhang J
    Nat Commun; 2021 Mar; 12(1):1999. PubMed ID: 33790276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Remarkable Anti-Breast Cancer Efficacy and Anti-Metastasis by Multifunctional Nanoparticles Co-Loading Squamocin, R848 and IR 780.
    Wang X; Liu X; Guo Y; Gong T; Lu W; Han M; Guo Y; Wang X
    Int J Nanomedicine; 2024; 19():4679-4699. PubMed ID: 38803997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
    Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
    Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.
    Lin W; Li C; Xu N; Watanabe M; Xue R; Xu A; Araki M; Sun R; Liu C; Nasu Y; Huang P
    Int J Nanomedicine; 2021; 16():2775-2787. PubMed ID: 33880023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs.
    Adzavon YM; Zhao P; Lv B; Liu M; Zhang X; Xie F; Yang L; Shang L; Zhang M; Li Q; Ma X
    Cytokine; 2017 Sep; 97():156-166. PubMed ID: 28648870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
    Thauvin C; Widmer J; Mottas I; Hocevar S; Allémann E; Bourquin C; Delie F
    Eur J Pharm Biopharm; 2019 Jun; 139():253-261. PubMed ID: 30981947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Intelligent Biomimetic Nanoplatform for Holistic Treatment of Metastatic Triple-Negative Breast Cancer
    Cheng Y; Chen Q; Guo Z; Li M; Yang X; Wan G; Chen H; Zhang Q; Wang Y
    ACS Nano; 2020 Nov; 14(11):15161-15181. PubMed ID: 33143424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
    Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polydopamine-coated ferric oxide nanoparticles for R848 delivery for photothermal immunotherapy in breast cancer.
    Yuan Z; He H; Zou J; Wang H; Chen Y; Chen Y; Lan M; Zhao Y; Gao F
    Int J Pharm; 2023 Sep; 644():123249. PubMed ID: 37467816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
    Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
    Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
    Lu Q; Qi S; Li P; Yang L; Yang S; Wang Y; Cheng Y; Song Y; Wang S; Tan F; Li N
    J Mater Chem B; 2019 Apr; 7(15):2499-2511. PubMed ID: 32255127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
    Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
    Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
    J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
    van den Ancker W; van Luijn MM; Ruben JM; Westers TM; Bontkes HJ; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
    Cancer Immunol Immunother; 2011 Jan; 60(1):37-47. PubMed ID: 20859626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
    Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
    Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
    Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.